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Abstract 
Bacterial vaginosis (BV) increases transmission of HIV, enhances the risk of preterm 
labour, and its associated malodour impacts the quality of life for many women. Clinical 
diagnosis primarily relies on microscopy to presumptively detect a loss of lactobacilli and 
acquisition of anaerobes. This diagnostic does not reflect the microbiota composition 
accurately as lactobacilli can assume different morphotypes, and assigning BV 
associated morphotypes to specific organisms is challenging. Using an untargeted 
metabolomics approach we identify novel biomarkers for BV in a cohort of 131 Rwandan 
women, and demonstrate that metabolic products in the vagina are strongly associated 
with bacterial diversity. Metabolites associated with high diversity and clinical BV include 
2-hydroxyisovalerate and γ-hydroxybutyrate (GHB), but not the anaerobic end-product 
succinate. Low diversity, and high relative abundance of lactobacilli, is characterized by 
lactate and amino acids. Biomarkers associated with diversity and BV are independent of 
pregnancy status, and were validated in a blinded replication cohort from Tanzania 
(n=45), in which we predicted clinical BV with 91% accuracy. Correlations between the 
metabolome and microbiota identified Gardnerella vaginalis as a putative producer of 
GHB, and we demonstrate production by this species in vitro. This work provides a 
deeper understanding of the relationship between the vaginal microbiota and biomarkers 
of vaginal health and dysbiosis. 
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Significance statement 
 
Bacterial vaginosis (BV) is the most common vaginal condition, characterized by an 
increase in bacterial diversity with a corresponding decrease in Lactobacillus species. 
Clinical diagnosis often relies on microscopy, which may not reflect the microbiota 
composition accurately. Here we identify novel biomarkers for BV, and demonstrate that 
the vaginal metabolome is strongly correlated with bacterial diversity. Metabolites 
associated with high diversity and clinical BV are common to both pregnant and non-
pregnant women, and were replicated in a blinded cohort with high sensitivity and 
specificity. We pinpoint the organism responsible for producing one of these biomarkers, 
and demonstrate production by this species in vitro. This work provides novel insight into 
the metabolism of the vaginal microbiota and provides a foundation for improved 
detection of disease. 
 
Introduction 
 
The vaginal microbiota is dominated by Lactobacillus species in most women, 
predominately by L. iners and L. crispatus (1-3). When these lactobacilli are displaced by 
a group of mixed anaerobes, belonging to the genus Gardnerella, Prevotella, Atopobium 
and others, this increase in bacterial diversity can lead to bacterial vaginosis (BV) (1-3). 
BV is the most common vaginal condition, affecting an estimated 30% of women at any 
given time (4). While many women remain asymptomatic (2-5), when signs and 
symptoms do arise they include an elevated vaginal pH>4.5, discharge, and malodor due 
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to amines (6-8). BV is also associated with a number of comorbidities, including 
increased transmission and acquisition of HIV and other sexually transmitted infections 
(9), and increased risk of preterm labour (10). 
 
In most instances, diagnosis is dependant upon microscopy of vaginal fluid to identify 
BV-like bacteria alone (Nugent Scoring (11)), or in combination with clinical signs (Amsel 
Criteria (12)). The precision and accuracy of these methods are poor due to the diverse 
morphology of vaginal bacteria, the observation that many women with BV are 
asymptomatic, and subjectivity in microscopic examination (13-15). Misdiagnosis creates 
stress for the patient, delays appropriate intervention and places a financial burden on 
the health care system. A rapid test based on stable, specific biomarkers for BV would 
improve diagnostic accuracy and speed, and reduce costs through improved patient 
management. . 
 
Metabolomics, defined as the complete set of small molecules in a given environment, 
has been utilized in a variety of systems to identify biomarkers of disease (16,17), and 
provide functional insight into shifts in microbial communities (18). Using an untargeted 
multiplatform metabolomics approach, combined with 16S rRNA gene sequencing, we 
demonstrate that the vaginal metabolome is driven by bacterial diversity, and identify 
novel biomarkers of clinical BV that can be reproduced in a blinded validation cohort. We 
further demonstrate that Gardnerella vaginalis, which has long been thought to be an 
important contributor to BV is the likely source of one of the most specific compounds. 
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This work illustrates how changes in community structure alter the chemical composition 
of the vagina, and identifies highly specific biomarkers for a common condition. 
 
Results 
 
The vaginal metabolome is most correlated with bacterial diversity 
We completed a comprehensive untargeted metabolomic analysis of vaginal fluid in two 
cross-sectional cohorts of Rwandan women: pregnant (P, n=67) and non-pregnant (NP, 
n=64) (Table S1). To normalize the amount of sample collected, vaginal swabs were 
weighed prior to and after collection and normalized to equivalent concentrations. This 
enabled us to collect precise measurements of metabolites in vaginal fluid. Metabolite 
profiling was carried out using both gas chromatography-mass spectrometry (GC-MS) 
and liquid chromatography-mass spectrometry (LC-MS), and microbiota composition by 
16S rRNA gene sequencing.  
 
The metabolome determined by GC-MS contained 128 metabolites (Table S2). We 
conducted a series of partial least squares (PLS) regression analyses to determine the 
single variable that could best explain the variation in the metabolome. In both cohorts, 
the diversity of the microbiota, as measured using Shannon’s Diversity (19), was the 
factor that explained the largest percent variation in the metabolome (Table S3), 
demonstrating that the vaginal metabolome is most correlated with bacterial diversity 
(Fig. 1A). Metabolites robustly associated with this diversity (95% CI <> 0)(Fig. 1B) were 
determined by jackknifing, and within this group, metabolites associated with extreme 
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diversity tended to have less variation in the jackknife replicates, and were common to 
both pregnant and non-pregnant women. This identified a core set of metabolites 
associated with diversity. 
 
The two cohorts overlapped by principal component analysis (PCA) (Fig S1), and no 
metabolites were significantly different between pregnant and non-pregnant women 
(unpaired t-test, Benjamini-Hochberg p > 0.01). Thus, the cohorts were combined for all 
further analysis. 
 
Metabolites and taxa associated with diversity 
A single PLS regression was performed on all samples with Shannon’s diversity as a 
continuous latent variable (Fig S2). Samples were then ordered by their position on the 
1st component of this PLS. The diversity indices, microbiota and metabolites associated 
with diversity of PLS ordered samples are shown in Fig. 2. The vaginal microbiota of 
Rwandan women were similar to women from other parts of the world, with the most 
abundant species being L. iners followed by L. crispatus (1-3,20) (Fig. 2B, Table S4). 
Women with high bacterial diversity were dominated by a mixture of anaerobes, including 
Gardnerella, Prevotella, Sneathia, Atopobium, Dialister and Megasphaera species.  
 
Fig. 2D displays metabolites robustly associated with bacterial diversity in both cohorts 
based on the PLS loadings in Fig 1B. Metabolites associated with high diversity include 
amines, which contribute to malodor (16-18), and a number of organic acid derivatives 
such as 2-hydroxyisovalerate (2HV), γ-hydroxybutyrate (GHB), 2-hydroxyglutarate and  
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2-hydroxyisocaproate. Low diversity was characterized by elevated amino acids, 
including the amine precursors lysine, ornithine and tyrosine. Many of these metabolites 
were detected by LC-MS, and trimethylamine (high diversity) and lactate (low diversity) 
were detected exclusively by this method (Table S5). The identities of metabolites of 
interest were confirmed with authentic standards when available (Fig. 2, asterisks). 
 
Succinate is not associated with diversity or clinical BV 
Succinate and lactate abundance are shown in panel E of Fig 2.  Succinate levels, and 
the succinate:lactate ratio have historically been associated with BV (21-23), and 
succinate has been postulated to play an immunomodulatory role (23). Here we show 
that succinate is not associated with bacterial diversity, nor is it significantly elevated in 
clinical BV as defined by Nugent scoring. This trend was independent of the detection 
method used. In addition, succinate was elevated in women dominated by L. crispatus 
compared with L. iners (unpaired ttest, Benjamini-Hochberg p < 0.01) (Fig S3), indicating 
L. crispatus may produce succinate in vivo, a phenomenon that has been demonstrated 
in vitro (24). 
 
Metabolites associated with diversity are sensitive and specific for clinical BV 
We defined clinical BV by the Nugent method, which is the current gold standard for BV 
diagnosis. This microscopy-based technique defines BV as a score of 7-10 when low 
numbers of lactobacilli morphotypes are observed, and high numbers of short rods 
presumed to represent BV associated bacteria are present. Nugent Normal (N) is defined 
as a score of 1-3, indicating almost exclusively Lactobacillus morphotypes. Intermediate 
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samples are given a score of 4-6 and do not fit into either group. Although Nugent scores 
correlated well with bacterial diversity in our study, it was apparent from the microbiota 
and metabolome profiles that two samples (41 and 145) had been misclassified by 
Nugent (Fig. 2A, red dots). The Nugent status of these samples was therefore corrected 
prior to all further analyses.  
 
In total we identified 49 metabolites that were significantly different between BV and N 
(unpaired t-test, Benjamini-Hochberg p < 0.01, Table S2). Nineteen of these have not 
been reported as differential in the literature, and 12 could not be identified. We 
determined the odds ratio (OR) for BV based on conditional logistic regressions of all 
individual metabolites detected by GC-MS (Table S2) to determine if the metabolites we 
associated with high bacterial diversity could accurately identify clinical BV as defined by 
Nugent scoring. Metabolites significantly elevated in Nugent BV (unpaired t-test, 
Benjamini-Hochberg p < 0.01) with OR > 1 are shown in Fig. 3A. Succinate was included 
as a comparator, although it did not reach significance. Both GHB and 2HV were 
significantly higher in women with BV, and had OR > 2.0, demonstrating they are novel 
indicators not only of high bacterial diversity, but also clinical BV. Receiver operating 
characteristics (ROC) curves built from LC-MS data determined that high 2HV, high 
GHB, low lactate and low tyrosine were the most sensitive and specific biomarkers for 
BV, with the largest area under the curve (AUC) achieved using the ratio of 2HV:tyrosine 
(AUC=0.993)(Fig 3B-D). ROC curves of GC-MS data identified similar trends, with the 
largest AUC achieved by the ratio of GHB:tyrosine (AUC=0.968) (Table S6).  
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We determined the optimal cut points for the GHB:tyrosine (0.621) and 2HV:tyrosine 
(0.882) ratios by selecting values which maximized the sensitivity and specificity for BV. 
Nugent intermediate samples grouped equally with N or BV based on these cut points, 
and intermediate-scored samples with smaller proportions of lactobacilli tended to group 
with BV (Fig 4). 
 
Validation of biomarkers in a blinded replication cohort from Tanzania 
We validated these biomarkers in a blinded cohort of 45 pregnant women from Mwanza, 
Tanzania (Bisanz at al, manuscript submitted). Using the 2HV:tyrosine cut point identified 
in the Rwanda data set, we identified Nugent BV with 89% sensitivity and 94% specificity 
in the validation set (AUC=0.946), demonstrating our findings are reproducible in an 
ethnically distinct population (Fig. 5, Table S7). The GHB:tyrosine ratio cut point was 
slightly less specific (88%), with an AUC of 0.948. We confirmed that succinate was not 
significantly different between Nugent N and BV in the validation set, nor was the 
succinate:lactate ratio. 
 
Identification of G. vaginalis as a producer of GHB 
Correlations between metabolites and all taxa indicated that tyramine, putrescine, and 
cadaverine were most correlated with Dialister (Pearson’s R = 0.53, 0.58, 0.69, p < 0.01) 
(Table S8), indicating this genus may contribute to malodor. We found that GHB was 
most correlated with G. vaginalis (Pearson’s R = 0.66, p< 0.01), while 2HV was most 
correlated with Dialister, Prevotella, and Atopobium (Pearson’s R = 0.61, 0.58, 0.55, p < 
0.01). 
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We chose to investigate the correlation between GHB and G. vaginalis, since this 
metabolite was novel, and predictive for both Shannon’s diversity and Nugent BV. 
Examination of available genomes showed that many strains of G. vaginalis possess a 
putative GHB dehydrogenase (annotated as 4-hydroxybutyrate dehydrogenase). We 
extracted metabolites from bacterial colonies grown on agar plates and reproducibly 
detected GHB in G. vaginalis extracts well above control levels (unpaired t-test, p< 0.05), 
but did not detect GHB from other species commonly associated with BV (Fig. 6, Table 
S9). These data suggest that G. vaginalis is the primary source of GHB detected in vivo. 
 
Discussion 
 
We have demonstrated that the vaginal metabolome is strongly correlated with bacterial 
diversity in both pregnant and non-pregnant Rwandan women, and identified 2HV and 
GHB as novel biomarkers of clinical BV, the latter of which we attribute to production by 
G. vaginalis. We obtained extremely accurate results by controlling for the mass of 
vaginal fluid collected, however we recognize this may not be logistically possible in a 
clinical setting. To circumvent this need we expressed biomarkers as ratios to the amino 
acid tyrosine, the most differential amino acid in health. Given the highly conserved 
nature of the vaginal microbiota across different populations and ethnicities (1-3,20), we 
expect these biomarkers to be globally applicable for the diagnosis of BV, and our ability 
to replicate findings in a distinct population strongly supports this theory. 
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Although G. vaginalis is strongly correlated with GHB in the vagina, it is important to note 
that no single organism has been identified as the cause of BV, and G. vaginalis is 
present in many women with a lactobacilli-dominated microbiota. However, as GHB is 
metabolized from succinate in other bacteria (25,26), a similar pathway could exist in G. 
vaginalis. Succinate-producing genera may therefore be required, making G. vaginalis 
essential, but not sufficient for GHB production in the vagina. This remains to be tested. 
 
The finding that succinate, an end product of anaerobic respiration, was not significantly 
elevated in women with BV was an unexpected outcome. This metabolite has historically 
been associated with the condition, but has not been tested in the context of a large 
untargeted metabolomic study. Other groups have reported large ranges in succinate 
abundance in women with BV (21,22), or used pooled samples (22). This, and our 
employment of necessary multiple testing corrections, could account for disparities in 
results. Differences in succinate abundance may have been more pronounced in 
previous studies if there were a lack of L. crispatus dominated women, which our data 
indicates is a succinate producer. There is increased expression of succinate producing 
pathways during BV (27), and therefore it is probable that large amounts are produced 
initially, but then rapidly converted to other compounds, such as GHB, by the microbiota 
and/or host.  
 
In addition to GHB, 2HV was identified as a highly specific novel biomarker for BV. 2HV 
is produced from breakdown of branched chain amino acids in humans (28) and some 
bacteria (29-31). When the trend for amino acid depletion in BV is considered, these 
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findings suggest increased amino acid catabolism in this condition. Some of these amino 
acids are converted to the amines cadaverine, tyramine, and putrescine, which are also 
associated with BV. These odor-causing compounds were most correlated with Dialister. 
Yeoman et al. (32) also linked amines to Dialister species, and the decarboxylating genes 
required for amine production are expressed by this genus in vivo (27). These data 
strongly suggest that Dialister is one of the genera responsible for malodor in the vagina. 
Given the small proportion of this genus in women with BV (0.2-8% in our study), this 
emphasizes the need for functional characterizations of the microbiome using 
metabolomic and transcriptomic approaches. 
 
The exact role, if any, of GHB and 2HV in the etiology of BV is unknown. Systemically 
GHB has both inhibitory and excitatory effects through activation of the GABA(B) and 
perhaps GABA(A) receptors in the brain, resulting in stimulatory and sedative effects if 
taken at high doses (33-35). The effects of GHB at other sites remain elusive. Future 
work should attempt to elucidate biological function of GHB and other novel metabolites 
to determine what effect (if any) they have on lactobacilli and the vaginal environment. 
 
In summary, we have demonstrated using an untargeted, multiplatform approach that 
differences in the vaginal metabolome are driven by bacterial diversity. Other 
metabolomic studies have focused on symptom-associated metabolites (31), changes 
after treatment (36), or longitudinal changes in a few subjects (37), and included 
exclusively non-pregnant women. We identified several novel biomarkers for clinical BV 
that are independent of pregnancy status, and replicated this result in a blinded cohort. 
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By combining high-throughput sequencing with advanced mass spectrometry techniques 
we have shown how in vivo metabolite information can be used to identify sources of 
metabolic end products in bacterial communities. These techniques can be applied to 
many systems where organisms may be fastidious or unculturable, and provide a much-
needed link between microbial composition and function. 
 
   Methods 
 
Clinical samples 
 
 Premenopausal women between the ages of 18 and 55 were recruited at the 
University of Kigali Teaching Hospital (CHUK) and the Nyamata District Hospital in 
Rwanda. The Health Sciences Research Ethics Board at Western University, Canada, 
and the CHUK Ethics Committee, Rwanda granted ethical approval for the study. 
Participants were excluded if they had reached menopause, had a current infection of 
gonorrhoea, Chlamydia, genital warts, active genital herpes lesions, active syphilis, 
urinary tract infections, received drug therapy that may affect the vaginal microbiome, 
had unprotected sexual intercourse within the past 48 hours, used a vaginal douche, 
genital deodorant or genital wipe in past 48 hours, had taken any probiotic supplement in 
past 48 hours, or were menstruating at time of clinical visit. After reviewing details of the 
study, participants gave their signed consent before the start of the study. For 
metabolome analysis, sterile Dacron polyester-tipped swabs (BD) were pre-cut with 
sterilized scissors and weighed in 1.5 ml microcentrifuge tubes prior to sample collection. 
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Using sterile forceps to clasp the pre-cut swabs, a nurse obtained vaginal samples for 
metabolomic analysis by rolling the swab against the mid-vaginal wall. A second full-
length swab was obtained for Nugent Scoring and 16S rRNA gene sequencing using the 
same method. Nugent Scoring was performed at CHUK by Amy McMillan. Vaginal pH 
was measured using pH strips. Samples were frozen within 2 hours of collection and 
stored at  -20 °C or below until analysis.  
 
Microbiome profiling 
 
 Vaginal swabs for microbiome analysis were extracted using the QIAamp DNA stool 
mini kit (Qiagen) with the following modifications: swabs were vortexed in 1 mL buffer 
ASL before removal of the swab and addition of 200 mg of 0.1 mm zirconia/silica beads 
(Biospec Products). Samples were mixed vigorously for 2 x 30 seconds at full speed with 
cooling at room temperature between (Mini-BeadBeater; Biospec Products). After heating 
to 95 °C for 5 minutes, 1.2 ml of supernatant was aliquoted into a 2ml tube and one-half 
an inhibitEx tablet (Qiagen) was added to each sample. All other steps were performed 
as per the manufacturers instructions. Sample amplification for sequencing was carried 
out using the forward primer 
(ACACTCTTTCCCTACACGACGCTCTTCCGATCTnnnn(8)CWACGCGARGAACCTTAC
C) and the reverse primer 
(CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTn(12)ACRACACGAGCTGAC
G 
AC) where nnnn indicates four randomly incorporated nucleotides, and (8) was a sample 
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nucleotide specific barcode. The 5’ end is the adapter sequence for the Illumina MiSeq 
sequencer and the sequences following the barcode are complementary to the V6 rRNA 
gene region. Amplification was carried out in 42 µL with each primer present at 0.8 
pMol/mL, 20 µL GoTaq hot start colorless master mix (Promega) and 2 µL extracted 
DNA. The PCR protocol was as follows: initial activation step at 95 °C for 2 minutes and 
25 cycles of 1 minute 95 °C, 1 minute 55 °C and 1 minute 72 °C. 
 
 All subsequent work was carried out at the London Regional Genomics Centre 
(LRGC, lrgc.ca, London, Ontario, Canada). Briefly, PCR products were quantified with a 
Qubit 2.0 Flourometer and the high sensitivity dsDNA specific fluorescent probes (Life 
Technologies). Samples were mixed at equimolar concentrations and purified with the 
QIAquick PCR Purification kit (QIAGEN). Samples were paired-end sequenced on an 
Illumina Mi-Seq with the 600 cycle version 3 reagents with 2x220 cycles. Data was 
extracted from only the first read, since it spanned the entirety of the V6 region including 
the reverse primer and barcode. 
 
 Resulting Reads were extracted and de-multiplexed using modifications of in-house 
Perl and UNIX-shell scripts with operational taxonomic units (OTUs) clustered at 97% 
identity, similar to our reported protocol (38). Automated taxonomic assignments were 
carried out by examining best hits from comparison the Ribosomal Database Project 
(rdp.cme.msu.edu) and manually curated by comparison to the Green genes database 
(greengenes.lbl.gov) and an in house database of vaginal sequences (Macklaim 
unpublished). Taxa with matches at least 95% similarity to query sequences were 
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annotated as such. OTUs were summed to the genus level except for lactobacilli, and 
rare OTUs found at less than 0.5% abundance in any sample removed. Table S1 
displays the nucleotide barcodes and their corresponding samples. Reads were 
deposited to the Short Read Archive (BioProject ID: xxx). To control for background 
contaminating sequences, a no-template control was also sequenced. Barplots were 
constructed with R {r-project.org } using proportional values.  
 
 To avoid inappropriate statistical inferences made from compositional data, centred 
log-ratios (clr), a method previously described by Aitchison (39) and adapted to 
microbiome data was used with paired t-tests for comparisons of genus and species level 
data (40). The Benjamini Hochberg (False Discovery rate) method was used to control for 
multiple testing with a significance threshold of 0.1. All statistical analysis, unless 
otherwise indicated, was carried out using R (r-project.org). 
Sample Preparation GC-MS 
 Vaginal swabs were pre-cut into 1.5 mL tubes and weighed prior to and after 
sample collection to determine the mass of vaginal fluid collected. After thawing, swabs 
were eluted in methanol-water (1:1) in 1.5 mL microcentrifuge tubes to a final 
concentration of 50 mg vaginal fluid/mL, which corresponded to a volume ranging from 
200-2696 µL, depending on the mass of vaginal fluid collected. A blank swab eluted in 
800 µL methanol-water was included as a negative control. All samples were vortexed for 
10 s to extract metabolites, centrifuged for 5 min at 10 621 g, vortexed again for 10 s 
after which time the brushes were removed from tubes. Samples were centrifuged a final 
time for 10 min at 10 621 g to pellet cells and 200 µL of the supernatant was transferred 
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to a GC-MS vial. The remaining supernatant was stored at -80 °C for LC-MS analysis. 
Next, 2 µL of 1 mg/mL ribitol was added to each vial as an internal standard. Samples 
were then dried to completeness using a SpeedVac. After drying, 100 µL of 2% 
methoxyamine-HCl in pyridine (MOX) was added to each vial for derivatization and 
incubated at 50 °C for 90 min. 100 µL N- Methyl-N-(trimethylsilyl) trifluoroacetamide 
(MSTFA) was then added and incubated at 50 °C for 30 min. Samples were then 
transferred to micro inserts before analysis by GC-MS (Agilent 7890A GC, 5975 inert 
MSD with triple axis detector). 1 µL of sample was injected using pulsed splitless mode 
into a 30 m DB5-MS column with 10 m duraguard, diameter 0.35mm, thickness 0.25 µm 
(JNW Scientific). Helium was used as the carrier gas at a constant flow rate of 1 ml/min. 
Oven temperature was held at 70 °C for 5 min then increased at a rate of 5 °C/min to 300 
°C and held for 10 min. Solvent delay was set to 13 min to avoid solvent and a large 
lactate peak, and total run time was 61 min. Masses between 25 m/z and 600 m/z were 
selected by the detector. All samples were run in random order and a standard mix 
containing metabolites expected in samples was run multiple times throughout to ensure 
machine consistency. 
Data Processing GC-MS 
 Chromatogram files were de-convoluted and converted to ELU format using the 
AMDIS Mass Spectrometry software (41), with the resolution set to high and sensitivity to 
medium. Chromatograms were then aligned and integrated using Spectconnect (42)  
(http://spectconnect.mit.edu), with the support threshold set to low. All metabolites found 
in the blank swab, or believed to have originated from derivatization reagents were 
removed from analysis at this time. After removal of swab metabolites, the IS matrix from 
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Spectconnect was transformed using the additive log ratio transformation (alr) (39) and 
ribitol as a normalizing agent (log2(x) / log2(ribitol)). Zeros were replaced with two thirds 
the minimum detected value on a per metabolite basis prior to transformation. All further 
metabolite analysis was performed using these alr transformed values.  
 Metabolites were initially identified by comparison to the NIST 11 standard 
reference database (http://www.nist.gov/srd/nist1a.cfm). Identities of metabolites of 
interest were then confirmed by authentic standards if available. 
Whole metabolome analysis  
 In order to visualize trends in the metabolome as detected by GC-MS, principal 
component analysis (PCA) was performed using pareto scaling. To determine the 
percentage of variation in the metabolome that could be explained by a single variable 
we performed a series of partial least squares (PLS) regressions where each variable 
was used as a continuous latent variable. We tested every taxa, pH, Nugent score, 
pregnancy status, Shannon’s diversity index and sample ID and compared the percent 
variation explained by the first component of each PLS. The variable with the highest 
value was determined to be most closely associated with the metabolome (Shannon’s 
Diversity). Analysis was conducted in R using the PLS package and unit variance 
scaling. Jackknifing with 20% sample removal and 10 000 repetitions was then applied to 
determine 95% confidence intervals for each metabolite. Metabolites with confidence 
intervals that did not cross zero in both cohorts (pregnant and non-pregnant) were 
considered significantly associated with diversity. Heatmaps of significant metabolites 
were constructed using the heatmap.2 function in R with average linkage hierarchical 
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clustering and manhattan distances. Unless specified otherwise, all tests for differential 
metabolites between groups were performed using unpaired t-test with a Benjamini-
Hochberg (False Discovery Rate) significance threshold of p < 0.01 to account for 
multiple testing and multiple group comparisons. Correlations between metabolites and 
taxa were performed using alr transformed values for metabolites and clr values with 128 
Monte Carlo instances for microbiota data in R using the ALDEx2 package (40). 
 Odds ratios of metabolites to identify Nugent BV from Normal were calculated from 
conditional logistic regressions performed on all metabolites using the glm function in R 
with 10 000 iterations and a binomial distribution. Metabolites with 95 % CI > 1 and p < 
0.01 (unpaired t-test, Benjamini-Hochberg corrected) were determined to be significantly 
elevated in Nugent BV. “Nugent BV” was defined by the clinical definition of a score of 7-
10, with a score of 0-3 being  “Nugent Normal”.  ROC curves and forest plots were built in 
R using the pROC and Gmisc packages respectively.   
Sample Preparation LC-MS 
 To confirm GC-MS findings, samples which had at least 100 µL remaining after GC-
MS were also analyzed by LC-MS. 100 µL of supernatant was transferred to vials with 
microinserts and directly injected into an Agilent 1290 Infinity HPLC coupled to a Q-
Exactive mass spectrometer (Thermo Fisher Scientific) with a HESI source. For HPLC, 2 
µL of each sample was injected into a ZORBAX Eclipse plus C18 2.1 x 50mm x 1.6 
micron column. Mobile phase (A) consisted of 0.1% formic acid in water and mobile 
phase (B) consisted of 0.1% formic acid in acetonitrile.  The initial composition of 100% 
(A) was held constant for 30 s and decreased to 0% over 3.0 min. Mobile phase A was 
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then held at 0% for 1.5 minutes and returned to 100% over 30s for a total run time of 5 
min.  
 Full MS scanning between the ranges of m/z 50-750 was performed on all samples 
in both positive in negative mode at 140 000 resolution.  The HESI source was operated 
under the following conditions: nitrogen flow of 25 and 15 arbitrary units for the sheath 
and auxiliary gas respectively, probe temperature and capillary temperature of 425 °C 
and 260 °C respectively and spray voltage of 4.8 kV and 3.9 kV in positive and negative 
mode respectively. The AGC target and maximum injection time were 3e6 and 500 ms 
respectively.  For molecular characterization, every tenth sample was also analyzed with 
a data dependent MS2 method where a 35 000 resolution full MS scan identified the top 
10 signals above a 8.3e4 threshold which were subsequently selected at a 1.2 m/z 
isolation window for MS2. Collision energy for MS2 was 24, resolution 17 500, AGC target 
1e5 and maximum injection time was 60ms. Blanks of pure methanol were run between 
every sample to limit carryover, and a single sample was run multiple times with every 
batch to account for any machine inconsistency. A blank swab extract was also run as a 
negative control.  
 For increased sensitivity, a separate LC-MS method was used for relative 
quantification of GHB in human samples. This was accomplished by selected ion 
monitoring in the mass range of 103.1 – 107.1 m/z in positive mode, and integrating the 
LC peak area of the [M+H+] ion (± 5 ppm). 
Data Processing LC-MS 
 After data acquisition Thermo .RAW files were converted to .MZML format using 
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ProteoWizard (43) and imported into MZmine 2.11 (44) (http://mzmine.sourceforge.net) 
for chromatogram alignment and deconvolution. Masses were detected using the Exact 
Mass setting and a threshold of 1E5. For Chromatogram Builder, minimum time was 0.05 
min, minimum height 3E3, and m/z threshold set to 0.025 m/z or 8 ppm. Chromatogram 
Deconvolution was achieved using the Noise Amplitude setting with the noise set to 5E4 
and signal to 1E5 for negative mode. Due to an overall greater signal and noise in 
positive mode, the noise was adjusted to 6E5 and signal to 6.5E5 for positive mode. Join 
aligner was used to combine deconvoluted chromatograms into a single file with the m/z 
threshold set to 0.05 m/z or 10 ppm, weight for m/z and RT set to 20 and 10 respectively, 
and a RT tolerance of 0.4 min.  After chromatograms were aligned, a single .CSV file was 
exported and all further analysis was carried out in R.  
 To confirm metabolites identified as significant by GC-MS in the LC-MS data set, 
the masses of metabolites of interest were searched in the LC-MS data set, and identities 
confirmed by MS2 using METLIN (45) and the Human Metabolome Database (46) online 
resources. Standards of metabolites of interest were also run to confirm identities when 
available. An unpaired t-test with Benjamini-Hochberg correction was used to determine 
metabolites significantly different between Nugent BV and Normal in the LC-MS data set. 
Metabolites with corrected p < 0.05 were considered statistically significant.  Metabolites 
detected exclusively by LC-MS that have previously been associated with BV or health 
(lactate, trimethylamine) were also included in this analysis. Data was log base 10 
transformed prior to data analysis and zeros replaced by 2/3 the minimum detected value 
on a per metabolite basis. To determine optimal cut points of biomarkers for diagnostic 
purposes, cut points were computed from LC-MS data using the OptimalCutpoints 
22	  	  
package in R (47) and the Youden Index method (48). 
Validation in blinded replication cohort 
Women between the ages of 18 and 40 were recruited from an antenatal clinic at the 
Nyerere Dispensary in Mwanza, Tanzania as part of a larger study on the effect of 
micronutrient supplemented probiotic yogurt on pregnancy. The study was approved by 
both the Medical research Coordinating Committee of the National Institute for Medical 
Research (NIMR), as well as from the Health Sciences Research Ethics Board at 
Western University. The study was registered with clinicaltrials.gov (NCT02021799). 
Samples were collected using the methods mentioned above, and Nugent scores 
performed by research technicians at NIMR in Mwanza, Tanzania. A subset of samples 
was selected based on these Nugent scores by a third party, who ensured there was not 
repeated sampling of any women. Amy McMillan, who performed metabolite analysis, 
was blinded to the Nugent scores for the duration of sample processing and data 
analysis. Biomarkers were quantified in samples by LC-MS using the protocols 
mentioned above. The study was unblinded after the submission of BV status based on 
the ratio cut points established in the Rwandan data set.  
Identification of putative GHB dehydrogenases in G. vaginalis strains 
The protein sequence of a bona fide 4-hydroxybutyrate (GHB) dehydrogenase isolated 
from Clostridium kluyveri (25) (GI:347073) was blasted against all strains of G. vaginalis 
in the NCBI protein database. Blast results identified multiple isolates containing a 
putative protein with 44-46% identity to the GHB dehydrogenase from C. kluyveri. The 
strain used for in vitro experiments (G.vaginalis ATCC 14018) was not present in the 
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NCBI protein database, however a nucleotide sequence in 14018 with 100% nucleotide 
identity to a putative 4-hydroxybutyrate dehydrogenases in strain ATCC 14019 
(GI:311114893) was identified, indicating potential for GHB production by strain 14018. 
In vitro extraction of GHB from vaginal isolates 
 Due to their fastidious nature, we found it difficult to obtain consistent growth of all 
vaginal strains in liquid media. To circumvent this, a lawn of bacteria was plated and 
metabolites were extracted from agar punches. All strains were grown on Columbia 
Blood Agar (CBA) plates using 5% sheep’s blood for 96h under strict anaerobic 
conditions, with the exception of L. crispatus, which was grown on de Man Rogosa Sharp 
(MRS) agar for 48 h. To extract metabolites, 16 agar punches 5 mm in diameter were 
taken from each plate and suspended in 3 mL 1:1 Me:H20. Samples were then sonicated 
in a water bath sonicater for 1h, transferred to 1.5 ml tubes after vortexing and spun in a 
desktop microcentrifuge for 10 min at 10 621 g to pellet cells. 200 µl of supernatant was 
then aliquoted for GC-MS described above. The area of each peak was integrated using 
ChemStation (Agilent) by selecting m/z 233 in the range of 14-16 min. Initial peak width 
was set to 0.042 and initial threshold at 10. An authentic standard of GHB was run with 
samples to confirm identification. Un-inoculated media was used as a control and 
experiments were repeated three times with technical duplicates.  
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Figures 
 
 
 
Fig. 1. The vaginal metabolome is most correlated with bacterial diversity. All analyses were 
carried out independently for non-pregnant (left) and pregnant (right) cohorts. Row (A) 
Partial least squares regression (PLS) scoreplot built from 128 metabolites detected by GC-
MS using bacterial diversity as a continuous latent variable. Each point represents a single 
woman (n=131). The position of points display similarities in the metabolome, with samples 
closest to one another being most similar. Circles are colored by diversity of the microbiota 
measured using Shannon’s diversity, where darker circles indicate higher diversity. Row (B) 
PLS regression loadings. Each point represents a single metabolite. Shaded circles indicate 
metabolites robustly associated with diversity in either cohort (Jackknifing, 95% CI < 0 > ). 
Shading of circles corresponds to the size of the confidence interval (CI) for each 
metabolite, where darker circles indicate narrower CIs. Venn diagram depicts overlap 
between metabolites associated with diversity in either cohort. Cad:Cadaverine, 
Tya:Tyramine, Put:Putrescine, MPh:Methylphosphate, 5AV:5-aminovalerate, HIC:2-
hydroxyisocaproate, HMV:2-hydroxy-3-methylvalerate, HV:2-hydroxyisovalerate, GHB: γ-
hydroxybutyrate. Ser:serine, Asp:aspartate, Glu:glutamate, Gly:glycine, Tyr:tyrosine. 
NAcLys:n-acetyl-lysine, Phe:phenylalanine, Orn:ornithine. 
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Fig. 2. Bacterial taxa and metabolites correlated with bacterial diversity in the vagina. 
Cohorts (non-pregnant and pregnant) were combined prior to analyses. Samples are 
ordered by their position on the first component (x-axis) of a partial least squares 
regression (PLS) built from metabolites using bacterial diversity as a continuous latent 
variable (see Fig. S2). Diversity was calculated using Shannon’s diversity (A). Red dots 
indicate samples clearly misclassified by Nugent. Barplots (B) display the vaginal 
microbiota profiled using the V6 region of the 16S rRNA gene. Each bar represents a 
single sample from a single woman, and each colour a different bacterial taxa. (C) 
Nugent Score (black=7-10 (BV), dark grey=4-6 (Int), light grey=1-3 (N), white=ND) and 
pregnancy status (black=P, grey=NP). (D) Heatmap of GC-MS detected metabolites 
which were robustly associated with diversity in both cohorts (Jackknifing, 95% CI <0>). 
Metabolites are clustered using average linkage hierarchical clustering. (E) Lactate and 
succinate abundance. Grey = ND. (*) indicates metabolites confirmed by authentic 
standards. 
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Fig. 3. Comparison of biomarkers to identify Nugent BV from Nugent N. (A) Odds ratios 
(OR) of metabolites with positive predictive value to identify Nugent BV. Bars represent 
95% Confidence Intervals. Metabolites were detected by GC-MS and P values generated 
from unpaired t-tests with a Benjamini-Hochberg correction to account for multiple testing 
(p < 0.01). (*) indicates metabolites confirmed by authentic standards. (B) Receiver 
operating characteristic (ROC) curves of metabolite ratios to identify Nugent BV from 
Nugent N. Ratios with largest area under the curve (AUC) are shown, along with 
succinate:lactate as a comparator. (C) AUC of selected metabolite ratios to identify 
Nugent BV. (D) AUC of metabolites alone to identify Nugent BV. Panels B-D were built 
from LC-MS data. GHB:γ-hyroxybutyrate, 2-HV:2-hydroxyisovalerate. 
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Fig. 4. Biomarker cut points effectively group Nugent Intermediate samples as BV or N. 
Barplots display the vaginal microbiota of Rwandan women sorted by (A) GHB:tyrosine 
or (B) 2HV:tyrosine. Each bar represents a single sample from a single woman and each 
colour a different bacterial taxa. Nugent scores are indicated below barplots. Black lines 
indicate ratio cut point for Nugent BV. Ratios were calculated from LC-MS data. 
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Fig. 5. Biomarker validation in a blinded replication cohort of 45 women from Tanzania. 
(A) BV status as defined by Nugent Score or ratio cut points identified in the Rwandan 
discovery data set. Black=BV,  Gray=N. (B) Heatmap of ratio values. (C) ROC curves 
and AUC of ratios to identify Nugent BV from N in the validation set. 2HV: 2-
hydroxyisovalerate, GHB: γ-hydroxybutyrate, Tyr: tyrosine. 
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Fig. 6. GHB is produced by Gardnerella vaginalis. GHB was extracted from bacteria 
grown on agar plates and detected by GC-MS. Values from three independent 
experiments are shown where each point was generated from an average of technical 
duplicates. * p < 0.05, unpaired t-test. 	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